The Addiction-Tech Money Isn't Drying Up. It's Just Betting Almost Entirely on AI Now.

Digital health startups raised $4.0 billion in the first quarter of 2026 across 110 deals — up from $3.0 billion a year earlier — and average deal size hit a five-year high of $36.7 million, per Rock Health’s quarterly report. That headline sounds like good news for anyone building addiction-treatment technology, Rize included. The number underneath it is more specific, and more demanding: AI-branded companies captured 54% of all that money, up from 37% the year before, with roughly a dozen megadeals of $100 million or more driving nearly 60% of the quarter’s total.

Capital isn’t leaving digital health. It’s concentrating on companies that can prove a model is doing the work, not just a website with a waitlist.

That’s a real shift in what investors are underwriting, and it matters specifically for the substance use treatment sector because so much of it — telehealth prescribing, insurance-verification tools, facility-matching platforms — has historically pitched itself on access rather than intelligence. Access alone increasingly reads to funders as infrastructure, not innovation, and infrastructure gets valued like infrastructure: useful, fundable, but not the kind of story that wins a megadeal in a market this concentrated.

The regulatory floor underneath telehealth-based addiction care, at least, isn’t moving out from under anyone this year. The DEA extended its telemedicine prescribing flexibilities through the end of 2026, meaning providers can still prescribe buprenorphine for opioid use disorder via audio-only telehealth without requiring an in-person visit first — the exact rule that companies like Ophelia, Bicycle Health, and Boulder Care depend on to operate. Worth naming plainly: this is an extension, not a permanent fix. It has lapsed and been renewed on a rolling basis for years now, which means every telehealth OUD company in the country is building a business on a regulatory foundation that gets re-confirmed roughly once a year instead of settled once and for all.

For the treatment-navigation and facility-matching platforms that make up a big share of this sector, the practical read isn’t to chase an AI narrative for its own sake. It’s that a searchable directory and a system that actually weighs insurance match, clinical service fit, and real-time bed availability together are now being treated by funders as two different categories of company — and increasingly valued that way. The bar for what counts as “doing the work” instead of just listing options has moved, and it’s not moving back.